GSK’s Nucala Secures NICE COPD Endorsement

Why It Matters

The approval gives NHS clinicians a proven, self‑injectable biologic to cut COPD flare‑ups, potentially reducing costly hospital admissions and easing pressure on the UK health system.

Key Takeaways

• NICE endorses Nucala for eosinophilic COPD add‑on therapy.
• Nucala cuts COPD exacerbations up to 21% versus standard care.
• Dupixent receives same NICE approval, expanding biologic options.
• GSK eyeing depemokimab (Exdensur) for future COPD use.
• COPD market projected $30.2 bn by 2033.

Pulse Analysis

The UK’s National Institute for Health and Care Excellence (NICE) has moved Nucala (mepolizumab) from asthma‑only status to a recommended add‑on for chronic obstructive pulmonary disease (COPD) with elevated eosinophils. The draft guidance draws on three Phase III trials—MATINEE, METREX and METREO—showing a 21 % reduction in annual exacerbations and a longer time to first flare when Nucala is combined with triple inhaled therapy. By allowing sub‑cutaneous self‑injection every four weeks, the recommendation promises both clinical benefit and a practical administration model for NHS patients.

The endorsement places Nucala alongside Sanofi’s Dupixent, which received a parallel NICE approval earlier this year after a previous rejection. Together they expand the biologic toolbox for a disease where fewer than 10 % of patients receive optimal care. While only a subset of COPD sufferers with high blood eosinophil counts qualify, the availability of two IL‑5/IL‑4 pathway agents could ease hospital admissions and reduce NHS spending on acute exacerbations. Analysts see the COPD biologics market gaining traction as clinicians seek to personalize maintenance therapy.

GSK is already positioning the next generation of IL‑5 inhibition, depemokimab (marketed as Exdensur), for COPD in the Phase III ENDURA programme, leveraging its recent asthma approval. If successful, the drug could extend GSK’s biologic franchise beyond Nucala and capture a share of the projected $30.2 bn COPD market by 2033. Meanwhile, eight other biologic candidates remain in late‑stage development, underscoring intense competition. The NICE decision therefore not only improves immediate patient outcomes but also accelerates a broader shift toward biologic‑driven COPD management across Europe and potentially the United States.